Objective: To examine the prevalence of falls, factors associated with falls and the relationship between falls and survival in older adults with multiple myeloma.
| INTRODUCTION
Falls are a common cause of morbidity and mortality among older adults. About one in three adults over age 65 fall each year. 1 Older adults with cancer have a greater risk for falls than their peers without cancer; those who report falls experience poorer quality of life and are at greater risk for severe toxicity from chemotherapy. [2] [3] [4] [5] Despite these observations, falls among older adults with cancer are a relatively understudied event, and little is known regarding the prevalence, sequelae, or factors predictive of falls in this population. 6, 7 Multiple myeloma (MM) is a cancer of older adults, with a median age of 69 at diagnosis. Geriatric issues, including comorbidities or dependence in daily activities, are common and have been associated with poorer prognosis in older adults with MM. 8, 9 However, the prevalence of falls, another geriatric syndrome, and their association with prognosis is unknown. Symptoms of MM and sequelae of its treatment, including bone loss, pain, functional decline and peripheral neuropathy, are highly prevalent and could be associated with a higher risk for falls and injurious falls. [10] [11] [12] [13] In the present study, we sought to determine the prevalence of falls in older patients with MM, to compare this rate with a cohort of matched controls without cancer, to examine factors associated with falls, and to assess the relationship between falls and overall survival.
| PATIENTS AND METHODS

| Data source
This study was performed under a protocol approved by the Washington 
| Statistical analysis
All data were analyzed using SAS enterprise guide 5.1. Casecontrol selection was performed using the PROC SURVEYSELECT function as previously described. 15 The characteristics of each cohorts were compared using ANOVA Table S1 .
| RESULTS
We identified 1889 MHOS surveys from 1229 unique MM patients in the SEER-MHOS dataset from 1998 to 2011. Of these patients, 485
completed the falls question at least once. One hundred seventy-one patients completed the falls question near the time of MM diagnosis and were included in cohort 1; an additional 234 completed the question one or more years following MM diagnosis and were included in cohort 2. One million, eight hundred and twelve thousand, six hundred and twenty-nine non-cancer MHOS surveys were available with the falls question completed; 513 of these were included in cohort 3
as matched controls for cohort 1.
Compared to non-cancer controls, MM patients were significantly more likely to report falls. Twenty-three percent of non-cancer controls reported falls in the 1-year prior, compared to 26% of MM patients in cohort 1% and 33% in cohort 2 (P = .012). Characteristics of the three cohorts are summarized in Table 3 .
| DISCUSSION
In the present study, we sought to determine the prevalence of falls in older patients with MM, to compare this rate with a cohort of matched controls without cancer, to examine factors associated with falls, and assess the relationship between falls and overall survival. We found that, in older patients recently diagnosed with MM, prior falls were more prevalent than in matched non-cancer controls, and there was an even higher prevalence of falls in the past year for patients surveyed more than a year subsequent to diagnosis. We found that older adults with MM who reported fatigue, poorer general health, or depression had greater odds of reporting a prior fall. We did not find an association between prior falls and survival in our analysis.
To our knowledge, this is the first report demonstrating that older adults with myeloma report a higher rate of prior falls than matched non-cancer controls. Multiple myeloma (MM) is associated with an increased risk of falling, occurring in over one-quarter of patients surveyed within a year of their MM diagnosis, and one-third of patients surveyed more than a year after diagnosis. Several studies have shown higher odds of falls in cancer survivors. 5, 10 Huang et al 16 showed that the rate of falls was higher in patients with lung and prostate cancer who were surveyed 1 or more years after diagnosis, compared to those surveyed before diagnosis. This increased prevalence of falls in patients with MM postdiagnosis is intriguing and will require prospective study to understand the relative contribution of toxicity of therapy and symptoms of disease to the increased risk of falls over time.
Falls are potentially preventable, particularly when individuals at greater risk are targeted for intervention. 17 Identification of factors associated with prior falls will inform future predictive models. In this study, depression was significantly associated with falls in this pop- 20, 21 and another did find a significant association between fatigue and falls in older adults with cancer. 22 In studies of individuals without cancer, fatigue alone is associated with falls, as is phenotypic frailty, of which self-reported exhaustion is a component. [23] [24] [25] The association between fatigue and falls may be directly linked through neuromuscular mechanisms. In one mechanistic study, participants walked on an inclined treadmill, and after fatiguing, older participants exhibited increased sway, slower reaction time, decreased lower leg strength, and increased fall risk. 26 Participants who reported that, overall, their health was fair or poor were 86% more likely to fall (aOR 1. survey item is nonspecific, asking "In general, would you say your health is: excellent/very good/good/fair/poor?" Respondents may have been taking into account comorbidities or functional status, both of which have been associated with falls in prior studies. 11, 22, [27] [28] [29] It is notable that the prevalence of numbness in the feet increased from 37% in patients surveyed at the time of diagnosis (cohort 1) to 63% in patients postdiagnosis (cohort 2). Peripheral neuropathy is a common toxicity of MM therapies, particularly thalidomide and bortezomib. [30] [31] [32] [33] Unfortunately, data on patient treatment is not available in this dataset. Numerous studies in other malignancies have shown an association between neurotoxic chemotherapy and falls. [11] [12] [13] 34 We did find a statistically significant association between neuropathy and falls in univariate analysis, but not on multivariate.
As older adults undergoing cancer therapy receive the majority of their healthcare in the oncology setting, it is imperative that fall risk be addressed during clinical follow-ups. However, falls assessments are not commonplace; in the current study, nearly one-third of patients who reported a prior fall had not talked with their doctor about falls or walking problems. Guerard et al 35 showed in a cohort of over 500 older adults with cancer, while almost 25% had fallen in the prior 6 months, a fall was documented in the medical record in only 10%
of those who had fallen, and only 6% were referred for intervention.
Because prior falls are strongly predictive of future falls, 36 this highlights a tremendous opportunity for more comprehensive and coordinated care to be provided to our older patients in the oncology clinic. This study also has several limitations. Self-report of falls as an outcome is frequently noted to be unreliable. In a cross-sectional study of falls in older adults with cancer by Overcash et al, participants were asked whether they had fallen in the prior 3 months, whether they had fallen since diagnosis, and whether they had fallen in the prior 12 months. More participants reported falls in the prior 3 months than in the prior 12 months, indicating that recall can be unreliable. 38 Consensus groups recommend that falls be assessed prospectively with falls calendars, grounded in a validated definition of falls to minimize subjective bias in what events would constitute a fall. 39 Another potential limitation of this study is that all participants were Medicare Advantage recipients, potentially limiting generalizability. Some have argued that enrollment of lower cost enrollees was incentivized in Medicare Advantage, potentially selecting for lower-risk participants. 40 However, that would suggest that the general population of older patients with MM enrolled in traditional feefor-service Medicare may be even more vulnerable and may have an even greater risk for falls than that seen in our study. Finally, claims data are not available in the SEER-MHOS database, so additional analyses of treatment, ascertainment of injurious falls and healthcare utilization are not possible. Future study will be required to understand the impact of myeloma treatments and their toxicities, such as neuropathy, on the risk of falls in older adults with myeloma.
In addition, further study is needed to understand the impact of falls on patients' quality-of-life and the incidence of fall-related injuries.
| CONCLUSION
In conclusion, older adults with MM are at greater risk of falls than their matched peers without MM and are associated with selfreported depression, fatigue, or poorer health. Complications of MM may put them at higher risk of injury resulting from a fall. Despite this, falls assessments are not commonplace during oncology clinical follow-ups, and falls are underreported by the patients in the clinic.
Simple but accurate screening assessments are needed to increase implementation of fall prevention into oncology practices.
